Results Of A Dutch Cost-Effectiveness Model Of Radium-223 In Comparison To Cabazitaxel, Abiraterone, And Enzalutamide In Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Docetaxel
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.1184
https://www.valueinhealthjournal.com/article/S1098-3015(15)03260-X/fulltext
Title :
Results Of A Dutch Cost-Effectiveness Model Of Radium-223 In Comparison To Cabazitaxel, Abiraterone, And Enzalutamide In Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Docetaxel
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)03260-X&doi=10.1016/j.jval.2015.09.1184
First page :
A459
Section Title :
Research Podium Presentations - Session 1 and Session 2
Open access? :
No
Section Order :
683